Disease relevance of Urogenital Neoplasms

• The results indicate that recombinant human G-CSF may be safely and effectively used against leukopenia after chemotherapy for urogenital cancer [1].
• PSA concentration was elevated (less than 10 ng/ml) in 84.4% of the patients with prostate cancer, in 14.1% of the patients with BPH, and in 10% of the patients with genitourinary cancer (as compared with 2% of the patients with benign genitourinary diseases) [2].
• Auditory toxicity effects of long-term cis-dichlorodiammineplatinum II therapy in genitourinary cancer patients [3].
• The effects of treatment on delayed cutaneous hypersensitivity responses (DNCB, croton oil, and recall antigen) in patients with genitourinary cancer [4].
• Current management of unusual genitourinary cancers. Part 1: Penile cancer [5].

High impact information on Urogenital Neoplasms

• Intranuclear sodium, potassium, and chloride contents were measured by energy-dispersive x-ray microanalysis in freeze-fractured, freeze-dried, bulk-tumor samples taken from 10 patients suffering from invasive urogenital cancers [6].
• Also, a potent cancer chemotherapeutic agent (FR901228), a histone deacetylase inhibitor, was able to induce endogenous CAR gene expression in several urogenital cancer cells [7].
• Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council [8].
• Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group [9].
• Fifteen patients with either gastrointestinal or genitourinary cancers were studied as controls; in 12 both the hands and feet were injected with antibodies to CEA and in the other three either the hands or feet [10].

Chemical compound and disease context of Urogenital Neoplasms

• The European Organization for Research and Treatment of Cancer genitourinary group has completed 2 parallel prospective randomized studies, one with 30 mg. mitomycin C and the other with 50 mg. doxorubicin as adjuvant intravesical treatment after transurethral resection of superficial transitional cell bladder carcinoma [11].
• Future directions for gemcitabine in the treatment of genitourinary cancer [12].
• Compound 2,4 dinitrofluorobenzene was used to sensitize 115 patients with genitourinary cancer to test their ability to be immunized with a newly encountered antigen [13].
• Brief communication: use of the multitargeted antifolate pemetrexed (Alimta) in genitourinary cancer [14].
• A multicenter cooperative study was conducted to evaluate the clinical efficacy and safety of cis-diammine(glycolato)platinum (254-S), a second-generation anticancer platinum complex, in the treatment of genitourinary cancers [15].

Biological context of Urogenital Neoplasms

• Oncogenic human papillomaviruses (HPVs), which play a major role in the pathogenesis of uterine cervix cancers and other urogenital cancers, encode E6 and E7 transforming proteins known to abrogate a p53-dependent G1 cell-cycle checkpoint activated by conventional acute-dose radiation exposure [16].
• BACKGROUND: We hypothesized that combined treatment with cyclooxygenase (Cox)-1 (catechin) and Cox-2 (NS398)-specific inhibitors would reduce cellular proliferation synergistically in genitourinary cancer [17].

Anatomical context of Urogenital Neoplasms

• Pelvic irradiation for urogenital cancer reduced monocyte release of tumour necrosis factor alpha (TNF-alpha) [18].
• Evaluation of cellular fluidity of peripheral blood lymphocytes from patients with urogenital cancers by a fluorescence polarization technique: PHA response and prognosis [19].

Gene context of Urogenital Neoplasms

• COX-2 inhibitors and other nonsteroidal anti-inflammatory drugs in genitourinary cancer [20].
• Carcinoembryonic antigen was measured in the urine and plasma of 108 patients with several types and various stages of genitourinary cancer [21].
• Glycopeptides (FSH, LH, TSH, prolactin) and glycoproteins in patients with genitourinary cancer [22].
• Sera from 20 patients with ALD, 38 patients with urogenital cancer, 22 patients with renal diseases, and from 18 healthy controls were studied [23].
• These first clinical trials of GM-CSF-secreting cancer cell vaccines for the treatment of genitourinary cancers have demonstrated both safety and bioactivity, in that very few side effects have been seen and anticancer immune responses have been detected [24].

Analytical, diagnostic and therapeutic context of Urogenital Neoplasms

• We used radioimmunoassay to determine TPA levels in a total of 150 serum samples from 88 patients with different types of genitourinary cancers [25].

References